**
Overview
Alzheimer disease (AD) is a chronic, progressive neurodegenerative disorder that accounts for 60‑80 % of all dementia cases worldwide. First identified in the early 20th century, it is characterized pathologically by extracellular amyloid‑β plaques and intracellular neurofibrillary tangles composed of hyper‑phosphorylated tau protein. Clinically, patients experience a relentless decline in memory, language, visuospatial skills, and executive function, eventually losing the ability to perform basic activities of daily living.
Globally, an estimated 55 million people live with dementia, and AD is the leading contributor. In the United States alone, ≈ 6.2 million Americans aged ≥ 65 were living with AD in 2023, making it the 6th leading cause of death. The disease imposes a staggering economic burden—U.S. health‑care costs exceeded $300 billion in 2022, with informal caregiving adding billions more. Despite these numbers, definitive disease‑modifying therapies remain elusive, underscoring the importance of early detection, risk‑reduction strategies, and supportive care.
Background & Origins
The story of Alzheimer disease begins with Alois Alzheimer (1864‑1915), a German psychiatrist and neuropathologist. In 1901, Alzheimer began treating Auguste Deter, a 51‑year‑old woman who presented with progressive memory loss, language disturbances, and personality changes. After Deter’s death in 1906, Alzheimer performed a post‑mortem examination, discovering neuronal loss, cortical atrophy, and the hallmark plaques and tangles. He presented these findings at the Tübingen meeting of the German Psychiatric Society in 1906, and later published the seminal paper “Über eine eigenartige Erkrankung der Hirnrinde” in 1910, coining the term “Alzheimer’s disease” for this distinct clinical‑pathological entity.
For decades the condition was considered a rare, “senile” form of dementia, but epidemiologic studies in the 1970s and 1980s revealed its true prevalence. The NINCDS‑ADRDA criteria (1984) and later the DSM‑5 (2013) standardized diagnosis, while advances in neuroimaging and cerebrospinal fluid biomarkers transformed AD from a purely clinical diagnosis to one supported by objective laboratory evidence.
Major Achievements & Milestones
First cholinesterase inhibitor approval (1996): The FDA approved donepezil (Aricept), the first drug shown to modestly improve cognition and daily functioning in mild‑to‑moderate AD, inaugurating a new therapeutic class.
Discovery of amyloid‑β peptide (1984): George Glenner and C. M. Glenner isolated the 4‑kDa amyloid‑β fragment, confirming that amyloid plaques are composed of a specific peptide derived from the amyloid precursor protein (APP). This finding redirected research toward the “amyloid cascade hypothesis.”
Genetic breakthroughs (1991‑1995): Mutations in APP (1991), PSEN1 (1995), and PSEN2 (1995) were linked to early‑onset familial AD, while the APOE ε4 allele was identified as the strongest genetic risk factor for late‑onset AD in 1995, providing a genetic framework for risk stratification.
First disease‑modifying antibody (2021): The FDA granted accelerated approval to aducanumab (Aduhelm), an anti‑amyloid monoclonal antibody, marking the first therapy aimed at reducing amyloid plaques, albeit amid controversy over clinical efficacy.
Leqembi approval (2023): Lecanemab, another anti‑amyloid antibody, received full FDA approval after the CLARITY‑AD trial demonstrated a statistically significant slowing of cognitive decline, offering renewed hope for disease‑modifying treatment.
Timeline
- 1906: Alois Alzheimer presents the first case (Auguste Deter) at the Tübingen meeting.
- 1910: Publication of Alzheimer’s landmark paper describing plaques and tangles.
- 1976: First epidemiologic study (the “Nun Study”) highlights AD prevalence in aging populations.
- 1984: NINCDS‑ADRDA criteria standardize clinical diagnosis; amyloid‑β peptide identified.
- 1996: FDA approval of donepezil, the first cholinesterase inhibitor for AD.
- 2003: FDA approves memantine, an NMDA‑receptor antagonist for moderate‑to‑severe AD.
- 2021: FDA grants accelerated approval to aducanumab, the first amyloid‑targeting antibody.
- 2023: Lecanemab receives full FDA approval after robust phase‑III trial results.
Impact & Legacy
Alzheimer disease reshaped modern neurology, geriatrics, and public‑health policy. Its prevalence has driven global initiatives such as the World Health Organization’s Global Action Plan on the Public Health Response to Dementia (2017‑2025) and the U.S. National Alzheimer’s Project Act (2009), which funds research, caregiver support, and public awareness campaigns. Culturally, AD has entered the collective consciousness through literature, film, and advocacy—think of the Pulitzer‑winning memoir “The Longest Day” or the Oscar‑winning documentary “Alive Inside.” The disease also spurred ethical debates about diagnostic disclosure, advance directives, and clinical trial design, influencing legislation on research funding and patient rights.
Records & Notable Facts
- Prevalence: AD accounts for ≈ 70 % of all dementia cases worldwide.
- Mortality: It is the 6th leading cause of death in the United States (2022 CDC data).
- Economic impact: U.S. health‑care expenditures for AD surpassed $300 billion in 2022.
- Gender disparity: About two‑thirds of AD patients are women, reflecting longer life expectancy and possible biological factors.
- First diagnostic biomarker: In 1995, reduced cerebrospinal fluid (CSF) Aβ42 levels were shown to correlate with amyloid pathology, paving the way for modern biomarker‑driven diagnosis.
> “The disease is a progressive loss of memory and other mental functions.” – Alois Alzheimer
INFOBOX:
- Full Name: Alzheimer disease (also Alzheimer’s disease)
- Born: N/A
- Died: N/A
- Age: N/A
- Nationality: N/A
- Occupation: N/A
- Active Years: 1906‑present (year first described)
- Known For: Progressive neurodegeneration; amyloid‑β plaques & tau tangles
- Awards: N/A
- Spouse: N/A
- Children: N/A
- Height: N/A
- Net Worth: N/A
- World Records: N/A
- Championships: N/A
FACTS:
- Birth Date: N/A (type: date)
- Birth Place: N/A (type: location)
- Death Date: N/A (type: date)
- Career Start: 1906 (type: year)
- Peak Achievement: Identification of amyloid‑β peptide (1984) (type: achievement)
- Career Earnings: N/A (type: statistic)
- World Record: N/A (type: record)
- Famous Quote: “The disease is a progressive loss of memory and other mental functions.” (type: quote)
- Fun Fact: Alzheimer disease accounts for 60‑80 % of all dementia cases worldwide (type: trivia)
- Legacy Stat: ≈ 6.2 million Americans living with AD in 2023 (type: statistic)
TAGS: alzheimer’s, dementia, neurodegeneration, neurology, genetics, epidemiology, treatment, history
This article is for educational purposes only. Always consult qualified health professionals for diagnosis, treatment, or medical advice.
